Episode 2: Bradley Campbell, Amicus Therapeutics

33:15
 
Share
 

Archived series ("Inactive feed" status)

When? This feed was archived on October 25, 2020 03:10 (3d ago). Last successful fetch was on August 30, 2019 02:27 (1y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 212361253 series 2394469
By Locust Walk. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

In this episode of Biotalk podcast, Josh Hamermesh, Vice President of Locust Walk interviews Bradley Campbell, President& COO of Amicus Therapeutics. Amicus is very much at the forefront developing and commercializing important therapies to treat a range of devastating rare and orphan diseases. In fact, this has been an eventful and exciting week at Amicus as the company announced the launch of Galafold in the UK. Galafold is the first oral treatment as well as the first precision medicine product for patients with Fabry’s Disease patients.

5 episodes